WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 464691
CAS#: unknown
Description: MBL-II-141 is a BCRP inhibitor.
MedKoo Cat#: 464691
Name: MBL-II-141
CAS#: unknown
Chemical Formula: C28H23BrN2O5
Exact Mass: 546.079
Molecular Weight: 547.405
Elemental Analysis: C, 61.44; H, 4.24; Br, 14.60; N, 5.12; O, 14.61
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: MBL-II-141; MBLII-141; MBL II-141; MBL-II141; MBL-II 141; MBLII141; MBL II 141;
IUPAC/Chemical Name: 5-((4-bromobenzyl)oxy)-N-(2-(5-methoxy-1H-indol-3-yl)ethyl)-4-oxo-4H-chromene-2-carboxamide
InChi Key: YOURSKBAKQLDQW-UHFFFAOYSA-N
InChi Code: InChI=1S/C28H23BrN2O5/c1-34-20-9-10-22-21(13-20)18(15-31-22)11-12-30-28(33)26-14-23(32)27-24(3-2-4-25(27)36-26)35-16-17-5-7-19(29)8-6-17/h2-10,13-15,31H,11-12,16H2,1H3,(H,30,33)
SMILES Code: BrC(C=C1)=CC=C1COC2=C(C(C=C(C(NCCC3=CNC4=C3C=C(OC)C=C4)=O)O5)=O)C5=CC=C2
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 547.405 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Hénin E, Honorat M, Guitton J, Di Pietro A, Payen L, Tod M. Pharmacokinetic interactions in mice between irinotecan and MBL-II-141, an ABCG2 inhibitor. Biopharm Drug Dispos. 2017 Jul;38(5):351-362. doi: 10.1002/bdd.2069. Epub 2017 Mar 23. PMID: 28207160.
2: Pires ADRA, Lecerf-Schmidt F, Guragossian N, Pazinato J, Gozzi GJ, Winter E, Valdameri G, Veale A, Boumendjel A, Di Pietro A, Pérès B. New, highly potent and non-toxic, chromone inhibitors of the human breast cancer resistance protein ABCG2. Eur J Med Chem. 2016 Oct 21;122:291-301. doi: 10.1016/j.ejmech.2016.05.053. Epub 2016 Jun 27. PMID: 27376492.
3: Payen L, Honorat M, Guitton J, Gauthier C, Bouard C, Lecerf-Schmidt F, Peres B, Terreux R, Gervot H, Rioufol C, Boumendjel A, Puisieux A, Di Pietro A. MBL- II-141, a chromone derivative, enhances irinotecan (CPT-11) anticancer efficiency in ABCG2-positive xenografts. Oncotarget. 2014 Dec 15;5(23):11957-70. doi: 10.18632/oncotarget.2566. PMID: 25474134; PMCID: PMC4323000.
4: Valdameri G, Genoux-Bastide E, Peres B, Gauthier C, Guitton J, Terreux R, Winnischofer SM, Rocha ME, Boumendjel A, Di Pietro A. Substituted chromones as highly potent nontoxic inhibitors, specific for the breast cancer resistance protein. J Med Chem. 2012 Jan 26;55(2):966-70. doi: 10.1021/jm201404w. Epub 2012 Jan 6. PMID: 22165858.
